Pages that link to "Q81638025"

The following pages link to BRCA1 promoter methylation predicts adverse ovarian cancer prognosis (Q81638025):

Displaying 45 items.

• A critical re-assessment of DNA repair gene promoter methylation in non-small cell lung carcinoma (Q21558626) (← links)
• BRCAness: finding the Achilles heel in ovarian cancer (Q24630872) (← links)
• Genomic/Epigenomic Alterations in Ovarian Carcinoma: Translational Insight into Clinical Practice (Q26740622) (← links)
• Ovarian Cancer: The Fallopian Tube as the Site of Origin and Opportunities for Prevention (Q26747279) (← links)
• Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer (Q27851709) (← links)
• Enriched transcription factor binding sites in hypermethylated gene promoters in drug resistant cancer cells (Q28390582) (← links)
• Evolution of the cancer genome (Q28678232) (← links)
• Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities (Q33315604) (← links)
• DNA methylation profiles of ovarian epithelial carcinoma tumors and cell lines (Q33533746) (← links)
• The role of BRCA status on the prognosis of patients with epithelial ovarian cancer: a systematic review of the literature with a meta-analysis (Q33553318) (← links)
• Changes in the mouse estrus cycle in response to BRCA1 inactivation suggest a potential link between risk factors for familial and sporadic ovarian cancer (Q33584787) (← links)
• Identification of candidate epigenetic biomarkers for ovarian cancer detection (Q33690825) (← links)
• Gross genomic alterations and gene expression profiles of high- grade serous carcinoma of the ovary with and without BRCA1 inactivation (Q33693203) (← links)
• BRCA-associated ovarian cancer: from molecular genetics to risk management (Q34032766) (← links)
• Differing clinical impact of BRCA1 and BRCA2 mutations in serous ovarian cancer (Q34305493) (← links)
• A genomic instability score in discriminating nonequivalent outcomes of BRCA1/2 mutations and in predicting outcomes of ovarian cancer treated with platinum-based chemotherapy (Q34599539) (← links)
• Inactivation of FBXW7/hCDC4-β expression by promoter hypermethylation is associated with favorable prognosis in primary breast cancer (Q34613635) (← links)
• Silencing of hypoxia-inducible tumor suppressor lysyl oxidase gene by promoter methylation activates carbonic anhydrase IX in nasopharyngeal carcinoma. (Q34704924) (← links)
• Methylation and protein expression of DNA repair genes: association with chemotherapy exposure and survival in sporadic ovarian and peritoneal carcinomas (Q34992260) (← links)
• DNA methylation changes in ovarian cancer: implications for early diagnosis, prognosis and treatment (Q37072060) (← links)
• Genetic and molecular changes in ovarian cancer (Q37094076) (← links)
• DNA hypermethylation, Her-2/neu overexpression and p53 mutations in ovarian carcinoma (Q37097138) (← links)
• Mechanism and pathobiologic implications of CHFR promoter methylation in gastric carcinoma (Q37344227) (← links)
• BRCA and Early Events in the Development of Serous Ovarian Cancer. (Q37513137) (← links)
• BRCA1 promoter hypermethylation in sporadic epithelial ovarian carcinoma: Association with low expression of BRCA1, improved survival and co-expression of DNA methyltransferases (Q37652536) (← links)
• Homologous recombination deficiency (HRD) testing in ovarian cancer clinical practice: a review of the literature. (Q37661436) (← links)
• Epigenetic therapy for the treatment of epithelial ovarian cancer: A clinical review (Q37724905) (← links)
• A critical re-appraisal of BRCA1 methylation studies in ovarian cancer (Q37783454) (← links)
• Epigenetic Drivers of Genetic Alterations (Q37797704) (← links)
• Epigenetic aberrations during oncogenesis. (Q37830385) (← links)
• Genomic instability in breast and ovarian cancers: translation into clinical predictive biomarkers (Q37933098) (← links)
• Identifying and exploiting defects in the Fanconi anemia/BRCA pathway in oncology. (Q38017504) (← links)
• Molecular-targeted therapies for ovarian cancer: prospects for the future (Q38036942) (← links)
• Epigenetics of breast cancer: Modifying role of environmental and bioactive food compounds (Q38825290) (← links)
• Development of a diagnostic microarray assay to assess the risk of recurrence of prostate cancer based on PITX2 DNA methylation (Q40222443) (← links)
• Biological markers of prognosis, response to therapy and outcome in ovarian carcinoma. (Q41006936) (← links)
• Clinical characteristics and outcomes of patients with BRCA1 or RAD51C methylated versus mutated ovarian carcinoma (Q49887782) (← links)
• The Role of DNA Methylation in Cancer. (Q52966734) (← links)
• Association of BRCA1/2 mutations with ovarian cancer prognosis: An updated meta-analysis. (Q55377222) (← links)
• Rucaparib in ovarian cancer: extending the use of PARP inhibitors in the recurrent disease (Q57169452) (← links)
• Homologous recombination deficiency in ovarian cancer: a review of its epidemiology and management (Q58801181) (← links)
• Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma (Q59126243) (← links)
• A five-DNA methylation signature act as a novel prognostic biomarker in patients with ovarian serous cystadenocarcinoma (Q59339898) (← links)
• Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial (Q59565062) (← links)
• PARP and PARG inhibitors in cancer treatment (Q89581160) (← links)